Addex Therapeutics Ltd. (ADXN) - Narx-foyda multiplikatori
Addex Therapeutics (ADXN) rivojlanish jarayonlari reagentlar yetishmovchiligi va Yevropa markazlaridagi uzilishlar tufayli to'xtab qolmoqda. Shu bilan birga, laboratoriyalarda dori sintezi uskunalarning yangilanishidan so'ng reja bo'yicha davom etmoqda. Osiyo importidagi qiyinchiliklar va patent nizolari xatarlarni yanada kuchaytirmoqda. Joriy ko'rsatkich -0.30 darajasida bo'lib, bu quyida ko'rsatilgan ushbu neyrodori ishlab chiqaruvchining narxlar dinamikasi bilan yaqqol namoyon bo'lmoqda.
Addex Therapeutics, Ltd. (ADXN) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- emitentning balans qiymati statistikasi:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati Addex Therapeutics|ADXN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Addex|ADXN - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Addex Therapeutics Ltd|ADXN - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli kredit va qarzlari Addex Therapeutics|Shoshilinch likvidlik addextherapeutics.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
ADXN - Kompaniyaning sof foydasi|Kutilayotgan sof daromad Addex Therapeutics|ADXN - P/E multiplikatori|Forvard P/E multiplikatori Addex Therapeutics Ltd.|ADXN - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Addex Therapeutics Ltd|ADXN - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Addex Therapeutics|ADXN - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi addextherapeutics.com|ADXN - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi Addex Therapeutics
Kompaniyaning umumiy tahlili:addextherapeutics.com, ADXN
P/E koeffitsiyenti foydaning bir birligining bozor qiymatini belgilaydi va investorlarning kelajakdagi pul oqimlari bo'yicha kutganlarini aks ettiradi. Kompaniyaning P/E baholash profilini tahlil qilish orqali aktiv haddan tashqari sotib olinganmi yoki o'sish potentsialiga egami, buni aniqlash mumkin. Ushbu metrika joriy aksiya narxining aksiya uchun foyda nisbati sifatida hisoblanadi. Addex Therapeutics (ADXN) uchun ushbu ko'rsatkich 2-bosqich klinik sinovlarining muvaffaqiyatlari va patent to'lovlariga sezgir hisoblanadi. Ushbu metrikaning tendentsiyasi Parkinson kasalligini davolashda erishilgan yutuqlar bilan birga investitsiya jozibadorligini tasdiqlaydi.
Muhim raqobatchilar
P/E multiplikatori biogen.com|P/E multiplikatori NBIX|Regencell Bioscience Ltd - Narx-foyda multiplikatori|P/E multiplikatori AXSM (Axsome Therapeutics Inc)|ACAD: Narx-foyda multiplikatori|Xenon Pharmaceuticals - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati vikingtherapeutics.com|SUPN (Supernus) - Narx-foyda koeffitsiyenti|Narx-foyda multiplikatori CPRX|Narx-foyda koeffitsiyenti DNLI|HRMY: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti BHVN (Biohaven Ltd.)|Bozor narxining sof foydaga nisbati AMLX|P/E multiplikatori TRVI (Trevi Therapeutics, Inc.)|Kompaniya qiymatining sof foydaga nisbati PRAX|Anavex Corp - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati CeriBell EEG|prothena.com (PRTA) - Narxning foydaga nisbati|Alector - Kompaniya qiymatining sof foydaga nisbati|ANNX (Annexon) - P/E multiplikatori|P/E multiplikatori Omeros Corp.|Narxning foydaga nisbati Neurogene Corp (NGNE)|ACIU: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori VYGR (Voyager Therapeutics)|neumoratx.com (NMRA) - Kapitalizatsiyaning foydaga nisbati|SCLX: Narx-foyda koeffitsiyenti|TVGN - P/E multiplikatori|ACOG (alphacognition.com) - Narx-foyda koeffitsiyenti|CGTX: Bozor narxining sof foydaga nisbati|IKT (Inhibikase Therapeutics) - P/E multiplikatori|cassavasciences.com (SAVA) - Biznesning o‘zini qoplash muddati|P/E multiplikatori ASRT|Narx-foyda koeffitsiyenti coyatherapeutics.com COYA|Narxning foydaga nisbati Vistagen VTGN|Biznesning o‘zini qoplash muddati Ovid Therapeutics Inc (OVID)|Acumen Pharmaceuticals - P/E multiplikatori|CRVO - P/E multiplikatori|ATHE: P/E multiplikatori|Narx-foyda multiplikatori CLNN|Narx-foyda koeffitsiyenti PEPG|Narx-foyda multiplikatori JUNS (Jupiter Neurosciences, Inc.)|Narxning foydaga nisbati Relmada Therapeutics (RLMD)|annovisbio.com - Narx-foyda multiplikatori|Narxning foydaga nisbati Grace Therapeutics GRCE|AIFF: Narx-foyda multiplikatori|ANEW Medical, Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals) - Narx-foyda koeffitsiyenti|MetaVia (MTVA) - P/E multiplikatori|Narxning foydaga nisbati NeurAxis|HSDT: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Passage Bio, Inc. (PASG)|NEUP - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori NERV (Minerva Neurosciences)|P/E multiplikatori athira.com ATHA|Alzamend - P/E multiplikatori|CYCN (Cyclerion Therapeutics) - Narx-foyda multiplikatori|PTIX: P/E multiplikatori|Narx-foyda multiplikatori KTTA|CRGT (Cortigent Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati avenuetx.com ATXI|Narx-foyda koeffitsiyenti BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. - Narx-foyda multiplikatori|Chromocell Therapeutics Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ELYM|ITCI: Narx-foyda koeffitsiyenti|longboardpharma.com - Bozor narxining sof foydaga nisbati|MRNS: P/E multiplikatori|NKGen Biotech Inc - Kompaniya qiymatining sof foydaga nisbati|NRBO (NeuroBo) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Sage Therapeutics Inc SAGE|Narxning foydaga nisbati Synaptogenix, Inc. (SNPX)|TRVN (trevena.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori VIGL (Vigil Neuroscience, Inc.)|P/E multiplikatori anewmeds.com WENA|CERE - Narxning foydaga nisbati
